Newbury Pharmaceuticals (NEWBRY) Life Science Conference 2026 summary

Strategic growth and portfolio expansion

• Expanded product pipeline from 11 to 46, focusing on Rx specialty and pharmacy channels between 2021 and 2026.

• Achieved 22 product launches, with 8 new launches in 2025, marking the highest annual launch count.

• Portfolio includes 29 licensed products and 17 with exclusive distribution rights, with direct sales in the Nordics and indirect international sales.

• Continued expansion through new license deals and strategic partnerships, including market entry into Finland.

• Regulatory changes temporarily paused international sales, with new orders anticipated in 2026.

Product launches and market performance

• 8 new launches in 2025 and 22 marketed products have diversified the portfolio and driven growth.

• First product launched in Finland in September 2025, expanding Nordic presence.

• Several launches delayed to late 2025 and early 2026 due to regulatory challenges.

• Sales in the Nordics increased by 56% in 2024/2025, with 17 products launched.

• International sales underperformed due to regulatory issues, with recovery expected in 2026.

Forward-looking statements and strategic focus

• Multiple launches planned for 2026, aiming to grow from 22 to 36 launched products.

• Strategic partnerships remain a key focus for portfolio and market expansion.

• Emphasis on leveraging new partnerships and expanding into branded innovative products.

• Continued investment in both specialty and volume generics for hospital and pharmacy channels.

• Market expansion and intensified international sales activities planned for 2025–2026.